{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T15:29:33Z","timestamp":1771687773345,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T00:00:00Z","timestamp":1392854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1245\/s10434-014-3543-7","type":"journal-article","created":{"date-parts":[[2014,2,19]],"date-time":"2014-02-19T16:45:42Z","timestamp":1392828342000},"page":"1616-1623","source":"Crossref","is-referenced-by-count":60,"title":["Phase I Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients with Locally Advanced Soft Tissue Sarcoma of the Extremity"],"prefix":"10.1245","volume":"21","author":[{"given":"Robert J.","family":"Canter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dariusz","family":"Borys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abimbola","family":"Olusanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Shang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Tamurian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arta M.","family":"Monjazeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,20]]},"reference":[{"issue":"9325","key":"3543_CR1","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","volume":"359","author":"B O\u2019Sullivan","year":"2002","unstructured":"O\u2019Sullivan B, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235\u201341.","journal-title":"Lancet."},{"issue":"6 Suppl 16","key":"3543_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.37265","volume":"29","author":"RK Jain","year":"2002","unstructured":"Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol. 2002;29(6 Suppl 16):3\u20139.","journal-title":"Semin Oncol."},{"key":"3543_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/sqb.2002.67.239","volume":"67","author":"RK Jain","year":"2002","unstructured":"Jain RK. Angiogenesis and lymphangiogenesis in tumors: insights from intravital microscopy. Cold Spring Harb Symp Quant Biol. 2002;67:239\u201348.","journal-title":"Cold Spring Harb Symp Quant Biol."},{"issue":"8","key":"3543_CR4","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/annonc\/mdh309","volume":"15","author":"SS Yoon","year":"2004","unstructured":"Yoon SS, et al. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol. 2004;15(8):1261\u20136.","journal-title":"Ann Oncol."},{"issue":"2","key":"3543_CR5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jss.2006.01.023","volume":"135","author":"SS Yoon","year":"2006","unstructured":"Yoon SS, et al. Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. J Surg Res. 2006;135(2):282\u201390.","journal-title":"J Surg Res."},{"issue":"12","key":"3543_CR6","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1054\/bjoc.2001.1837","volume":"84","author":"K Yudoh","year":"2001","unstructured":"Yudoh K, et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer. 2001;84(12):1610\u20135.","journal-title":"Br J Cancer."},{"issue":"4","key":"3543_CR7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1634\/theoncologist.12-4-465","volume":"12","author":"S Senan","year":"2007","unstructured":"Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist. 2007;12(4):465\u201377.","journal-title":"Oncologist."},{"issue":"2","key":"3543_CR8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijrobp.2007.02.001","volume":"68","author":"BG Czito","year":"2007","unstructured":"Czito BG, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys. 2007;68(2):472\u20138.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"3543_CR9","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6602584","volume":"92","author":"A Awada","year":"2005","unstructured":"Awada A, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21\u00a0days on\/7\u00a0days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005;92(10):1855\u201361.","journal-title":"Br J Cancer."},{"issue":"5","key":"3543_CR10","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23(5):965\u201372.","journal-title":"J Clin Oncol."},{"issue":"16","key":"3543_CR11","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","volume":"24","author":"MJ Ratain","year":"2006","unstructured":"Ratain MJ, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505\u201312.","journal-title":"J Clin Oncol."},{"issue":"2","key":"3543_CR12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125\u201334.","journal-title":"N Engl J Med."},{"issue":"13","key":"3543_CR13","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/djh182","volume":"96","author":"WR Parulekar","year":"2004","unstructured":"Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst. 2004;96(13):990\u20137.","journal-title":"J Natl Cancer Inst."},{"issue":"9","key":"3543_CR14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMe058007","volume":"352","author":"R Kurzrock","year":"2005","unstructured":"Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med. 2005;352(9):930\u20132.","journal-title":"N Engl J Med."},{"issue":"9","key":"3543_CR15","first-page":"3911","volume":"32","author":"D Shah","year":"2012","unstructured":"Shah D, et al. Complete pathologic response to neoadjuvant radiotherapy is predictive of oncological outcome in patients with soft tissue sarcoma. Anticancer Res. 2012;32(9):3911\u20135.","journal-title":"Anticancer Res."},{"issue":"10","key":"3543_CR16","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1245\/s10434-010-1156-3","volume":"17","author":"RJ Canter","year":"2010","unstructured":"Canter RJ, et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol. 2010;17(10):2578\u201384.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"3543_CR17","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.2001.19.13.3203","volume":"19","author":"FC Eilber","year":"2001","unstructured":"Eilber FC, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203\u20139.","journal-title":"J Clin Oncol."},{"issue":"19","key":"3543_CR18","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099\u2013109.","journal-title":"Cancer Res."},{"issue":"19","key":"3543_CR19","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1158\/0008-5472.CAN-07-1473","volume":"67","author":"JP Plastaras","year":"2007","unstructured":"Plastaras JP, et al. Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007;67(19):9443\u201354.","journal-title":"Cancer Res."},{"issue":"5","key":"3543_CR20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","volume":"59","author":"YS Chang","year":"2007","unstructured":"Chang YS, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59(5):561\u201374.","journal-title":"Cancer Chemother Pharmacol."},{"issue":"58","key":"3543_CR21","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1038\/sj.onc.1208003","volume":"23","author":"JH Lim","year":"2004","unstructured":"Lim JH, et al. Ras-dependent induction of HIF-1alpha785 via the Raf\/MEK\/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene. 2004; 23(58):9427\u201331.","journal-title":"Oncogene."},{"issue":"6","key":"3543_CR22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1470-2045(07)70169-9","volume":"8","author":"JS Wunder","year":"2007","unstructured":"Wunder JS, et al. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 2007;8(6):513\u201324.","journal-title":"Lancet Oncol."},{"issue":"5","key":"3543_CR23","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","volume":"19","author":"S Frustaci","year":"2001","unstructured":"Frustaci S, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238\u201347.","journal-title":"J Clin Oncol."},{"issue":"Suppl 2","key":"3543_CR24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000073366","volume":"65","author":"S Frustaci","year":"2003","unstructured":"Frustaci S, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology. 2003;65 Suppl 2:80\u20134.","journal-title":"Oncology."},{"issue":"9","key":"3543_CR25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0959-8049(01)00083-1","volume":"37","author":"E Gortzak","year":"2001","unstructured":"Gortzak E, et al. A randomised phase II study on neo-adjuvant chemotherapy for \u2018high-risk\u2019 adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096\u2013103.","journal-title":"Eur J Cancer."},{"issue":"5","key":"3543_CR26","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00000421-200210000-00009","volume":"25","author":"R Petrioli","year":"2002","unstructured":"Petrioli R, et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol. 2002;25(5):468\u201373.","journal-title":"Am J Clin Oncol."},{"issue":"4","key":"3543_CR27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1155\/2000\/126837","volume":"4","author":"T Brodowicz","year":"2000","unstructured":"Brodowicz T, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma. 2000;4(4):151\u201360.","journal-title":"Sarcoma."},{"issue":"3","key":"3543_CR28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","volume":"113","author":"N Pervaiz","year":"2008","unstructured":"Pervaiz N, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113(3):573\u201381.","journal-title":"Cancer."},{"issue":"19","key":"3543_CR29","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","volume":"27","author":"RG Maki","year":"2009","unstructured":"Maki RG, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133\u201340.","journal-title":"J Clin Oncol."},{"issue":"3","key":"3543_CR30","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cncr.26334","volume":"118","author":"M Mehren von","year":"2012","unstructured":"von Mehren M, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012;118(3):770\u20136.","journal-title":"Cancer."},{"issue":"5","key":"3543_CR31","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.ijrobp.2005.04.028","volume":"62","author":"J Li","year":"2005","unstructured":"Li J, et al. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys. 2005;62(5):1477\u201385.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"4 Suppl 3","key":"3543_CR32","first-page":"7","volume":"19","author":"RK Jain","year":"2005","unstructured":"Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 2005;19(4 Suppl 3):7\u201316.","journal-title":"Oncology (Williston Park)."},{"issue":"10","key":"3543_CR33","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1245\/s10434-010-1156-3","volume":"17","author":"RJ Canter","year":"2010","unstructured":"Canter RJ, et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma. Ann Surg Oncol. 2010;17(10):2578\u201384.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"3543_CR34","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2106\/00004623-199807000-00011","volume":"80","author":"JS Wunder","year":"1998","unstructured":"Wunder JS, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80(7):1020\u201333.","journal-title":"J Bone Joint Surg Am."},{"issue":"1","key":"3543_CR35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.CAN-13-1186","volume":"74","author":"AI Romero","year":"2014","unstructured":"Romero AI, et al. Regulation of CD4+NKG2D+ Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15R\u03b1 and NKG2D triggering. Cancer Res. 2014;74(1):68\u201380.","journal-title":"Cancer Res."},{"issue":"3","key":"3543_CR36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.20.3.791","volume":"20","author":"MW Kattan","year":"2002","unstructured":"Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20(3):791\u20136.","journal-title":"J Clin Oncol."},{"issue":"2","key":"3543_CR37","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2004.03.009","volume":"60","author":"G Pitson","year":"2004","unstructured":"Pitson G, et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int J Radiat Oncol Biol Phys. 2004;60(2):522\u20136.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"3543_CR38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.radonc.2010.10.007","volume":"97","author":"D Roberge","year":"2010","unstructured":"Roberge D, et al. Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother Oncol. 2010;97(3):404\u20137.","journal-title":"Radiother Oncol."},{"issue":"14","key":"3543_CR39","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1002\/cncr.24375","volume":"115","author":"PW Chung","year":"2009","unstructured":"Chung PW, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer. 2009; 115(14):3254\u201361.","journal-title":"Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3543-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-014-3543-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3543-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T15:51:36Z","timestamp":1565193096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-014-3543-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["3543"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-3543-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}